A Biotech Bash - Recs and Wrecks Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : A Biotech Bash - Recs and Wrecks

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Czechsinthemail who wrote (13)	8/25/1997 9:04:00 PM
From: r. peter Dale	of 171

Well, I feel supremely underqualified to respond to the posts that have appeared here. I guess its all that humbleness training in graduate school finally paying off. So guys and gals this will be my approach: in order to maintain the original tenor of this thread, I will comment in a general fashion on information posted. But I will generally NOT read the threads associated with specific companies. Why join the chorus when a cappella awaits. Feel free to lambaste my pitiful ignorance. I tend to ignore almost all the financial pronouncements related to biotechs. Shocking. I also ignore all the impressive consultants hired by biotechs. I'm such a fool. Both are fluff compared to the necessity of good science. This is why I provided instructions in using the PubMed site (see # 5). Baird: I'm not familiar with either Avigen or Sibia. Since my training was in Neuroscience (glial expression of growth factors) and have not followed the field recently, I'm very curious about how SIB-1508Y works. Does it preserve nigral neurons? Does it inhibit the breakdown of Dopamine? In other words, has Sibia found a way to treat the disease or are they treating the symptoms (like L-dopa). My brief search indicates that one article has been published for this compound - since no abstract was available it appears its a nicotinic AchR agonist. So it must work downstream of the dopaminergic defect...? This appears to be novel approach. My only hesitation with Sibia (again from a VERY brief scan - please correct me) was flagged by the info in your post: you list too many diseases. Curing one symptom of one of those ailments would be a highly lucrative breakthrough and would be reason enough to own the stock. This may be the case with Sibia. But neurobiology does not live and die by the nicotinic cholinergic receptor. Baird & Rick: I spoke with Univec today. I'll report back here soon. In short, not much learned but they are the sole supplier to WHO and the demand from this one source alone is expanding rapidly. Rick - your assistance here is greatly appreciated. Jenny says hi; I'm working on the non-EAE email (clue: copper chelation). More later. Best wishes, Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next